Go Deep
Medexus Pharmaceuticals Inc.
Medexus Pharmaceuticals Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 17,979 | -55.2 | 2.32 | 0.55 | 337.76 |
Medexus Pharmaceuticals Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 28,585,000.0 | 24,652,000.0 | 25,324,000.0 | 24,741,000.0 |
| Net Profit | 544,000.0 | -2,675,000.0 | 80,000.0 | -315,000.0 |
| EPS | 0.0 | — | 0.0 | -0.0 |
Medexus Pharmaceuticals Inc. Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 99,332,000.0 | 108,332,000.0 | 113,054,000.0 | 108,096,000.0 |
| Net Profit | -2,394,000.0 | 2,247,000.0 | -214,000.0 | 1,221,000.0 |
| EPS | -0.1 | 0.1 | -0.0 | 0.1 |
Medexus Pharmaceuticals Inc. Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 147,284,000.0 | 171,838,000.0 | 155,733,000.0 | 161,329,000.0 | — |
| Total Liabilities | 98,294,000.0 | 119,695,000.0 | 125,410,000.0 | 138,881,000.0 | — |
| Total Equity | 48,990,000.0 | 52,143,000.0 | 30,323,000.0 | 22,448,000.0 | — |
Medexus Pharmaceuticals Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Mar 2026
Cash & short-term investments 4.4%Receivables 10.1%Inventory 22.6%Intangible assets 49.2%Other assets 13.4%
How it's funded — Mar 2026
Short-term debt 1.5%Long-term debt 13.6%Payables 5.6%Other liabilities 46.0%Shareholders' equity 33.3%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 6.5 | 24.0 | 5.3 | 13.1 |
| Receivables | 14.9 | 13.3 | 24.0 | 22.4 |
| Inventory | 33.3 | 35.3 | 30.8 | 22.8 |
| Fixed assets (tangible) | 0.4 | 0.7 | 0.8 | 0.9 |
| Intangible assets | 72.5 | 81.6 | 74.4 | 80.7 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 19.7 | 17.0 | 20.5 | 21.5 |
| Liabilities & equity | ||||
| Short-term debt | 2.2 | 37.0 | 15.7 | 42.7 |
| Long-term debt | 20.1 | 0.2 | 34.2 | 27.4 |
| Payables | 8.2 | 5.7 | 7.8 | 10.2 |
| Other liabilities | 67.8 | 76.8 | 67.8 | 58.6 |
| Shareholders' equity | 49.0 | 52.1 | 30.3 | 22.4 |
| Net tangible assets | -23.5 | -29.5 | -44.1 | -58.2 |
Medexus Pharmaceuticals Inc. Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 18,874,000.0 | 24,034,000.0 | 18,714,000.0 | -1,444,000.0 | — |
| Investing Activities | -17,403,000.0 | -6,001,000.0 | -3,478,000.0 | -1,721,000.0 | — |
| Financing Activities | -18,921,000.0 | 796,000.0 | -23,048,000.0 | 6,405,000.0 | — |